Rigel Pharmaceuticals (RIGL) Capital Expenditures (2010 - 2025)
Rigel Pharmaceuticals' quarterly Capital Expenditures came in at -$12000.0 in Q4 2025, down 146.15% year-on-year from $26000.0 in Q4 2024, and down 146.15% quarter-over-quarter from $26000.0 in Q4 2024.
Rigel Pharmaceuticals has reported Capital Expenditures for 15 years, with the latest figure at -$12000.0 in Q4 2025.
- For the quarter ending Q4 2025, Capital Expenditures fell 146.15% year-over-year to -$12000.0; the trailing twelve-month figure through Dec 2025 stood at $276000.0 (up 9.52% YoY), and the FY2024 full-year result was $36000.0, changed N/A from the prior year.
- Capital Expenditures for Q4 2025 stood at -$12000.0, down from $26000.0 in the prior quarter.
- The five-year high for Capital Expenditures was $407000.0 in Q2 2021, with the low at -$36000.0 in Q2 2022.
- Average Capital Expenditures over 4 years is $109100.0, with a median of $72000.0 recorded in 2021.
- Year-over-year, Capital Expenditures surged 1025.0% in 2021 and plunged 146.15% in 2025.
- Tracing RIGL's Capital Expenditures over 4 years: stood at -$21000.0 in 2021, then soared by 447.62% to $73000.0 in 2022, then tumbled by 64.38% to $26000.0 in 2024, then plunged by 146.15% to -$12000.0 in 2025.
- The last three Capital Expenditures figures came in at -$12000.0 (Q4 2025), $26000.0 (Q4 2024), and $73000.0 (Q4 2022), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 133.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 230.60 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 21.83 Mn |
| 10 | Rigel Pharmaceuticals | 551.62 Mn | 404.94 Mn | 54.21 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -12,000.00 |
| Dec 31, 2025 | -12,000.00 |
| Dec 31, 2024 | 26,000.00 |
| Dec 31, 2024 | 26,000.00 |
| Dec 31, 2022 | 73,000.00 |
| Dec 31, 2022 | 73,000.00 |
| Sep 30, 2022 | 189,000.00 |
| Sep 30, 2022 | 189,000.00 |
| Jun 30, 2022 | -36,000.00 |
| Jun 30, 2022 | -36,000.00 |
| Mar 31, 2022 | 224,000.00 |
| Mar 31, 2022 | 224,000.00 |
| Dec 31, 2021 | -21,000.00 |
| Dec 31, 2021 | -21,000.00 |
| Sep 30, 2021 | 170,000.00 |
| Sep 30, 2021 | 170,000.00 |
| Jun 30, 2021 | 407,000.00 |
| Jun 30, 2021 | 407,000.00 |
| Mar 31, 2021 | 71,000.00 |
| Mar 31, 2021 | 71,000.00 |
| Dec 31, 2020 | 504,000.00 |
| Dec 31, 2020 | 504,000.00 |
| Sep 30, 2020 | 195,000.00 |
| Sep 30, 2020 | 195,000.00 |
| Jun 30, 2020 | -44,000.00 |
| Jun 30, 2020 | -44,000.00 |
| Mar 31, 2020 | 607,000.00 |
| Mar 31, 2020 | 607,000.00 |
| Dec 31, 2019 | 611,000.00 |
| Dec 31, 2019 | 611,000.00 |
| Sep 30, 2019 | 352,000.00 |
| Sep 30, 2019 | 352,000.00 |
| Jun 30, 2019 | 115,000.00 |
| Jun 30, 2019 | 115,000.00 |
| Mar 31, 2019 | 377,000.00 |
| Mar 31, 2019 | 377,000.00 |
| Dec 31, 2018 | 69,000.00 |
| Dec 31, 2018 | 69,000.00 |
| Sep 30, 2018 | 156,000.00 |
| Sep 30, 2018 | 156,000.00 |
| Jun 30, 2018 | 684,000.00 |
| Jun 30, 2018 | 684,000.00 |
| Mar 31, 2018 | 197,000.00 |
| Mar 31, 2018 | 197,000.00 |
| Dec 31, 2017 | 53,000.00 |
| Dec 31, 2017 | 53,000.00 |
| Sep 30, 2017 | 56,000.00 |
| Sep 30, 2017 | 56,000.00 |
| Jun 30, 2017 | 14,000.00 |
| Jun 30, 2017 | 14,000.00 |
| Mar 31, 2017 | 41,000.00 |
| Mar 31, 2017 | 41,000.00 |
| Dec 31, 2016 | 6,000.00 |
| Dec 31, 2016 | 6,000.00 |
| Sep 30, 2016 | 252,000.00 |
| Sep 30, 2016 | 252,000.00 |
| Jun 30, 2016 | 225,000.00 |
| Jun 30, 2016 | 225,000.00 |
| Mar 31, 2016 | 321,000.00 |
| Mar 31, 2016 | 321,000.00 |
| Dec 31, 2015 | 134,000.00 |
| Dec 31, 2015 | 134,000.00 |
| Sep 30, 2015 | 307,000.00 |
| Sep 30, 2015 | 307,000.00 |
| Jun 30, 2015 | 73,000.00 |
| Jun 30, 2015 | 73,000.00 |
| Mar 31, 2015 | 32,000.00 |
| Mar 31, 2015 | 32,000.00 |
| Dec 31, 2014 | 200,000.00 |
| Dec 31, 2014 | 200,000.00 |
| Sep 30, 2014 | -40,000.00 |
| Sep 30, 2014 | -40,000.00 |
| Jun 30, 2014 | 75,000.00 |
| Jun 30, 2014 | 75,000.00 |
| Mar 31, 2014 | 178,000.00 |
| Mar 31, 2014 | 178,000.00 |
| Dec 31, 2013 | 168,000.00 |
| Dec 31, 2013 | 168,000.00 |
| Sep 30, 2013 | 128,000.00 |
| Sep 30, 2013 | 128,000.00 |
| Jun 30, 2013 | 249,000.00 |
| Jun 30, 2013 | 249,000.00 |
| Mar 31, 2013 | 676,000.00 |
| Mar 31, 2013 | 676,000.00 |
| Dec 31, 2012 | 601,000.00 |
| Dec 31, 2012 | 601,000.00 |
| Sep 30, 2012 | 384,000.00 |
| Sep 30, 2012 | 384,000.00 |
| Jun 30, 2012 | 818,000.00 |
| Jun 30, 2012 | 818,000.00 |
| Mar 31, 2012 | 1.57 Mn |
| Mar 31, 2012 | 1.57 Mn |
| Dec 31, 2011 | 185,000.00 |
| Dec 31, 2011 | 185,000.00 |
| Sep 30, 2011 | 561,000.00 |
| Sep 30, 2011 | 561,000.00 |
| Jun 30, 2011 | 697,000.00 |
| Jun 30, 2011 | 697,000.00 |
| Mar 31, 2011 | 860,000.00 |
| Mar 31, 2011 | 860,000.00 |
| Dec 31, 2010 | 928,000.00 |
| Dec 31, 2010 | 928,000.00 |
| Sep 30, 2010 | 897,000.00 |
| Sep 30, 2010 | 897,000.00 |